Skip to content

Latest medicine updates

198 updates found

New New Updated Updated Retired Retired

NARROW IT DOWN

MEDICINE NAME

CHANGES

Date range

DOCUMENT TYPE

STATUS

Pil
levocarnitine
Updated 28-Apr-17
Updated
  • Improved presentation of PIL
Pil
l-carnitine
Updated 28-Apr-17
Updated
  • Improved presentation of PIL
Pil
l-carnitine
Updated 28-Apr-17
Updated
  • Improved presentation of PIL
Pil
l-carnitine
Updated 28-Apr-17
Updated
  • Improved presentation of PIL
Pil
l-carnitine
Updated 28-Apr-17
Updated
  • Improved presentation of PIL
Pil
levothyroxine sodium
Updated 28-Apr-17
Updated
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - driving and using machines
  • Change to section 3 - use in children/adolescents
  • Change to section 6 - date of revision
Pil
levothyroxine sodium
Updated 28-Apr-17
Updated
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - driving and using machines
  • Change to section 3 - use in children/adolescents
  • Change to section 6 - date of revision
SPC
cetirizine dihydrochloride
Updated 28-Apr-17
Updated
  • Change to section 1 - Name of the medicinal product
SPC
live attenuated rotavirus vaccine
Updated 28-Apr-17
Updated
  • Change to section 4.8 - Undesirable effects
Pil
daratumumab
Updated 28-Apr-17
Updated
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
SPC
Vexol 1% Eye Drops, Suspension
rimexolone
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
Pil
Vexol 1% Eye Drops, Suspension
rimexolone
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
SPC
Tobravisc 3.0 mg/ml eye drops, solution
tobramycin
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
Pil
Tobravisc 3.0 mg/ml Eye Drops, Solution
tobramycin
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
Pil
Mydriacyl 0.5%
tropicamide
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
SPC
Mydriacyl 0.5%
tropicamide
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
SPC
Isopto Alkaline
hypromellose
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
Pil
Isopto Alkaline
hypromellose
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
SPC
Emadine 0.05% w/v, Eye Drops, Solution
emedastine difumarate
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
Pil
Emadine 0.05% w/v Eye Drops Solution
emedastine difumarate
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
SPC
Ciloxan 3mg/g Eye Ointment
ciprofloxacin hydrochloride
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
Pil
Ciloxan 3mg/g Eye Ointment
ciprofloxacin hydrochloride
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
SPC
Alomide Allergy 0.1% eye drops, Solution
lodoxamide trometamol
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
Pil
Alomide Allergy 0.1% eye drops, Solution
lodoxamide trometamol
Retired 28-Apr-17
Alcon Laboratories (U.K) Limited
Retired
  • Transfer of Marketing Authorisation Holder
SPC
apraclonidine hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
SPC
imatinib mesilate
Updated 28-Apr-17
Updated
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
SPC
levothyroxine sodium
Updated 28-Apr-17
Updated
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
SPC
paracetamol, codeine phosphate
Updated 28-Apr-17
Updated
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text
SPC
paracetamol, codeine phosphate
Updated 28-Apr-17
Updated
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text
SPC
paracetamol, codeine phosphate
Updated 28-Apr-17
Updated
  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text
SPC
calcium carbonate, colecalciferol; cholecalciferol
Updated 28-Apr-17
Updated
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
SPC
calcium carbonate, colecalciferol; cholecalciferol
Updated 28-Apr-17
Updated
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
SPC
calcium carbonate, colecalciferol; cholecalciferol
Updated 28-Apr-17
Updated
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
SPC
calcium carbonate, colecalciferol; cholecalciferol
Updated 28-Apr-17
Updated
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Pil
nefopam hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
SPC
tramadol hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
Pil
pirfenidone
Updated 28-Apr-17
Updated
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 3 - dose and frequency
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
SPC
tramadol hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
Pil
teriflunomide
Updated 28-Apr-17
Updated
  • Change to section 2 - driving and using machines
  • Change to section 2 - excipient warnings
  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
Pil
dexamethasone, tobramycin
Updated 28-Apr-17
Updated
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
SPC
tramadol hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
SPC
tramadol hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
SPC
tramadol hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
SPC
tramadol hydrochloride
Updated 28-Apr-17
Updated
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
SPC
dexamethasone, tobramycin
Updated 28-Apr-17
Updated
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
Pil
levonorgestrel
Updated 28-Apr-17
Updated
  • Change to section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision
Pil
hypromellose
Updated 28-Apr-17
Updated
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
SPC
phenytoin sodium
Updated 28-Apr-17
Updated
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.8 - Undesirable effects - how to report a side effect
Pil
agalsidase beta
Updated 28-Apr-17
Updated
  • Improved presentation of PIL
SPC
levetiracetam
Updated 28-Apr-17
Updated
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects - how to report a side effect

Page 1 of 4 Next

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue